KRAS and neoplasm: Furthermore, the SuPAR may predict response to therapy in colorectal cancer patients, as patients with low levels of circulating suPAR and a wild-type KRAS tumor benefit from treatment with oxaliplatin and cetuximab, as compared to patients with wild-type KRAS and high levels of SuPAR (Tarpgaard et al., 2015).